--- title: "Ocular Therapeutix Shares Surge Following Reports Of Stronger Sanofi Bid" type: "News" locale: "en" url: "https://longbridge.com/en/news/272721717.md" description: "Ocular Therapeutix shares surged after reports indicated that Sanofi is preparing a revised bid for the company, following a rejected offer of $16 per share. The stock rose approximately 21% in premarket trading, reflecting strong investor interest. Sanofi's potential acquisition aims to enhance its presence in the wet age-related macular degeneration market, with Ocular's drug Axpaxli in late-stage development. Currently, Ocular shares are trading at $11.20, showing mixed technical indicators and a bullish momentum score of 69.06/100, suggesting caution for investors." datetime: "2026-01-15T15:30:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/272721717.md) - [en](https://longbridge.com/en/news/272721717.md) - [zh-HK](https://longbridge.com/zh-HK/news/272721717.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/272721717.md) | [繁體中文](https://longbridge.com/zh-HK/news/272721717.md) # Ocular Therapeutix Shares Surge Following Reports Of Stronger Sanofi Bid **Ocular Therapeutix, Inc.** (NASDAQ:OCUL) shares are trading higher Thursday after reports suggested **Sanofi** is preparing a revised bid for the company. - Ocular Therapeutix stock is surging to new heights today. Why is OCUL stock up today? ## Sanofi Prepares Higher Bid Sanofi is readying an improved takeover offer for Ocular Therapeutix after the company rejected a prior proposal, according to several outlets, citing a report from French publication La Lettre. The report states that Sanofi previously approached Ocular with a discreet offer of $16 per share in September, which was turned down by Ocular's board. Since then, Sanofi CEO **Paul Hudson** and the company's management team have reportedly been working on an enhanced bid. Ocular Therapeutix shares rose roughly 21% in premarket trading Thursday before pulling back. The stock had been trading around $10.50 per share at the time of the initial approach, implying a market capitalization of approximately $2.2 billion. Reports indicate that a potential acquisition would provide Sanofi with exposure to the wet age-related macular degeneration market. Ocular's tyrosine kinase inhibitor Axpaxli is currently in late-stage development for wet AMD, with topline data from the SOL-1 study expected in the first quarter of 2026 and data from the SOL-R study anticipated in the first half of 2027. The report also noted that Sanofi has recently increased its M&A activity. In December, the company agreed to acquire **Dynavax Technologies** for nearly $2.2 billion, with the transaction expected to close in the first quarter of 2026. ## Mixed Technical Indicators For OCUL Currently, Ocular Therapeutix is trading 1.7% above its 20-day simple moving average (SMA) but is 0.7% below its 50-day SMA, indicating mixed signals in the short term. Over the past 12 months, shares have increased approximately 48.34%, and the stock is positioned closer to its 52-week highs than lows. The RSI is at 39.46, which is considered neutral territory, while the MACD is below its signal line, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum. ## Benzinga Edge Rankings Below is the Benzinga Edge scorecard for Ocular Therapeutix, Inc. (OCUL), highlighting its strengths and weaknesses compared to the broader market: - **Momentum**: Bullish (Score: 69.06/100) — Stock is outperforming the broader market. **The Verdict:** Ocular’s Benzinga Edge signal reveals a classic ‘High-Flyer’ setup. While the Momentum (69.06) confirms the strong trend, the lack of additional rankings suggests that investors should remain cautious. **OCUL Price Action:** At the time of writing, Ocular shares are trading 1.17% higher at $11.20, according to data from Benzinga Pro. _Image Via Shutterstock_ ### Related Stocks - [Ocular Therapeutix, Inc. (OCUL.US)](https://longbridge.com/en/quote/OCUL.US.md) ## Related News & Research - [Assenagon Asset Management S.A. Has $7.54 Million Position in Ocular Therapeutix, Inc. $OCUL](https://longbridge.com/en/news/280899731.md) - [Under the Radar: Proven Cash Generators Hiding in Plain Sight](https://longbridge.com/en/news/281226777.md) - [Nextensa obtains permit for Lake Side project](https://longbridge.com/en/news/281569157.md) - [Paradigm mulls prediction market entry with trading terminal, market making desk: Fortune](https://longbridge.com/en/news/281410102.md) - [High Gas Prices May Prompt Consumers to Reduce Drive-Thru Visits, Research Shows](https://longbridge.com/en/news/281060780.md)